two most prescribed oral anti-diabetic medicines -- metformin and
sulfonylurea -- apart from the well characterized fluid-related events
common to both Avandia and Actos.
2. In three epidemiological studies of databases with more than one
million diabetic patients, the risk of heart attack was similar for
Avandia compared to other anti-diabetic agents. A database study
comparing Avandia to Actos showed no difference between the two.
3. Two large epidemiology studies presented to the FDA Advisory Committee
and conducted independently of GSK by WellPoint and by the Department
of Defense/Tricare also showed no increased rates of heart attack
between Avandia and Actos.
Importantly, only Avandia has been shown to control blood sugar for up to five years and to be 32 percent more effective than metformin and 63 percent more effective than sulfonylurea in maintaining blood sugar control over the long-term. We know from clinical studies that effective treatment of diabetes requires intensive, long-term, day-to-day control of blood sugar levels to reduce the risk of serious complications (e.g., blindness, kidney failure, limb amputation, nerve injury) and ultimately save lives. Avandia is the most widely studied oral medication for Type 2 Diabetes, and is an important option for physicians who often need to prescribe several different diabetes medicines in combination to help their patients maintain blood sugar control.
The FDA is engaged in a full, objective analysis of the science, and will make its independent recommendations on the appropriate use of oral anti- diabetic medicines. GSK continues to support Avandia as safe and effective when used appropriately.
GlaxoSmithKline -- one of the world's leading research-based
pharmaceutical and healthcare companies -- is committed to improving the
quality of human life by enabling people to do more, feel better and liv
Copyright©2007 PR Newswire.
All rights reserved